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Targeted Ultrasound for MR-Detected
Lesions in Breast Cancer Patients
Objective: To investigate the usefulness of targeted ultrasound (US) in the
identification of additional suspicious lesions found by magnetic resonance (MR)
imaging in breast cancer patients and the changes in treatment based on the
identification of the lesions by the use of targeted US. 
Materials and Methods: One-hundred forty nine patients who underwent
breast MR imaging for a preoperative evaluation of breast cancer between
January 2002 and July 2004 were included in the study. We searched all cases
for any additional lesions that were found initially by MR imaging and investigated
the performance of targeted US in identifying the lesions. We also investigated
their pathological outcomes and changes in treatment as a result of lesion identifi-
cation. 
Results: Of the 149 patients with breast cancer, additional suspicious lesions
were detected with MR imaging in 62 patients (42%). Of the 69 additional lesions
found in those 62 patients, 26 (38%) were confirmed as cancers by histology.
Thirty-eight lesions in 31 patients were examined with targeted US and were his-
tologically revealed as cancers in 18 (47%), high risk lesions in two (5%), benign
lesions in 15 (39%), and unidentified lesions in three (8%). The cancer rate was
statistically higher in lesions with a US correlate than in lesions without a US cor-
relate (p = 0.028). Of 31 patients, the surgical plan was altered in 27 (87%). The
use of targeted US justified a change in treatment for 22 patients (81%) and mis-
led five patients (19%) into having an unnecessary surgical excision.
Conclusion: Targeted US can play a useful role in the evaluation of additional
suspicious lesions detected by MR imaging in breast cancer patients, but is limit-
ed in lesions without a US correlate. 
he high sensitivity of magnetic resonance imaging (MRI) to detect breast
cancer enhances the evaluation of multifocal or multicentric lesions.
Despite the occasional presence of additional suspicious lesions detected
only by MRI, MR-guided percutaneous biopsies have not yet prevailed all over the
world, because of a lack of commercially available equipment, a lack of real-time feed-
back, and the time-consuming procedure (1, 2). However, if careful reexamination
with another conventional modality is used to visualize the additional MR detected
lesions, this would allow a conventional means of biopsy guidance. 
Often, MRI results in a change to surgical treatment plans based on the presence of
additional suspicious lesions in patients with breast cancer. Considering the scheduling
constrictions regarding surgical time, the fastest and most readily available method is
needed for the preoperative localization of additional MR lesions, if possible, as well as
histological confirmation. Ultrasound (US) dominates image guidance for breast
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Tinterventions with its practical aspects and cost effective-
ness. Nevertheless, few studies have reported on the
usefulness of directed US investigations of breast lesions
that were first detected with MRI in determining the
probability of cancer and in the discovery of US correlates
(3, 4). It is important to know the value and limitations of
ultrasound in the evaluation of additional suspicious MR
lesions in this special group. The purpose of our study was
to investigate the usefulness of targeted US for identifying
additional suspicious lesions found on MRI only for the
preoperative evaluation of breast cancer and to determine
whether the use of preoperative breast targeted US had an
impact on subsequent surgical management.
MATERIALS AND METHODS
Patients and Lesions
The institutional review board approved this study and
did not require the approval of patients nor their informed
consent for review of their images and records. From
January 2002 to July 2004, 303 women underwent breast
MRI examinations were initially considered for this study.
The primary inclusion criterion of this retrospective
analysis was a preoperative MRI in patients with histologi-
cally confirmed breast cancer. Among the 303 women, 213
patients had confirmed breast cancer. Of these patients, 61
who underwent neoadjuvant chemotherapy were excluded
because of a possible chemotherapeutic effect causing
different kinetics and morphology of suspicious lesions (5).
Three patients who did not undergo surgery in our institu-
tion were also excluded. The remaining 149 patients were
included in this study. 
The average age of the patients in the present study was
50 years (range 23 to 79 years). Indications for an MR
examination included preoperative staging before planned
breast conserving therapy to exclude multicentricity in
patients who had one mammographic or sonographic
suspicious lesion (n = 123), a search for an occult tumor
with axillary metastases of suspected breast origin (n = 5)
and a postoperative examination to rule out residual
disease (n = 21). 
A review of the MR images and final reports by an
experienced radiologist specialized in breast imaging was
conducted. We searched the cases with additional
suspicious breast lesions that were initially detected by
MRI. By the definition of Liberman et al. (6), MR lesions
were considered to be additional sites if they were located
in a different breast quadrant than the index cancer, if they
were in the same quadrant but were separated from the
index cancer by at least 1.0 cm of intervening normal-
appearing tissue on MRI, or if they were in the same
quadrant and contiguous with the index cancer but
extended at least 4.0 cm beyond the site of the index
cancer. Typically benign appearing enhancing lesions, i.e.
those with a circumscribed margin or delayed enhance-
ment were excluded.
If MRI revealed additional suspicious breast lesions other
than the index cancer, a targeted US performed by the
radiologist who interpreted the MR images was
recommended to look for a US correlates amenable to
further biopsy or localization. Although there were no
standardized protocols to follow, a targeted US examina-
tion by the radiologists who had knowledge of the MRI
findings was performed for the clinical and mammographi-
cal occult lesions. When targeted US was performed, the
additional suspicious breast lesions were classified into two
groups based on whether or not they had a US correlates.
We investigated their pathological outcomes and changes
in treatment for these patients. We compared the rate of
identifying additional cancers between the lesions with and
without a US correlate using the Fisher’s exact test. 
The 31 patients that did not receive targeted US
consisted of two groups; one of the groups in whom the
breast US was performed before the breast MR imaging
and did not correlate with any additional detectable lesion
by MRI and the other group with mammographic microcal-
cifications, which were not detected initially and did
correlate with the MRI lesions. These lesions were
confirmed by surgical excision or were followed with a
subsequent examination. 
Breast MRI Technique
Breast MRI was performed with the patient prone in a
1.5-T commercially available imager (Signa; GE Medical
System, Milwaukee, WI) with the use of a dedicated
surface breast coil. The MRI sequence used in this study
included a fat suppressed axial fast spin echo T2-weighted
sequence (4000/120, repetition time msec/echo time msec)
and fat-suppressed unilateral sagittal dynamic imaging.
Contralateral sagittal dynamic imaging was obtained on
the next day. Dynamic imaging was performed with a T1-
weighted three-dimensional, fat-suppressed fast spoiled
gradient-echo sequence (17.3/1.3 ms; flip angle, 30 ) three
times (one before and two after a rapid bolus injection of
0.1 mmol/kg gadopentetate dimeglumine [Magnevist;
Berlex, Wayne , NJ]) (7). Section thickness was held
between 1.0 2.0 mm without an intersection gap with a
256 192 matrix, an 18 24 cm field of view, and a scan
time of 3 4 minutes. Two sequential post-contrast scans
were obtained without a break, beginning immediately
after the saline flush. Standard subtraction images were
obtained by subtracting the precontrast images from the
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pixel basis. Reverse subtraction images were obtained by
subtracting the last postcontrast image from the early peak
postcontrast image. If the lesion demonstrated a kinetic
pattern showing an early rise and an early washout, the
lesion would be observed with the remaining high signal
intensity on reverse subtraction images. We regarded these
lesions as kinetically suspicious lesions. If any kinetic
curves were equivocal, the morphologic features were
considered together. If the lesion has a spiculate or an
irregular margin, we regarded it as a morphological
suspicious lesion. If a lesion had morphologic features that
indicated it was probably benign but reverse subtraction
images demonstrated a high signal intensity lesion, this was
also considered to be suspicious (8). Criteria for the
features of suspicious non-mass-like enhancements
included linear, ductal, and segmental patterns. Maximum
intensity projection images were reformed from the
subtraction images. 
Breast US and US-Guided Intervention Technique
Breast US examinations were performed by one of four
breast imaging radiologists using a 7 10 MHz linear
transducer (Logiq 700; General Electric, Milwaukee, WI,
or HDI 5000; Philips Medical Systems, Bothell, WA). At
the time of breast US examination, prior MR images were
made available for direct correlation. 
Thirty-eight lesions in 31 patients were performed with
targeted US. Of 21 patients with correlated suspicious
enhancing lesions that were evident on US, eight
underwent US-guided core biopsy for the suspicious lesion
and 10 underwent US-guided localization, one with US-
guided hook-wire localization and the remaining nine with
US-guided carbon marking (9). In the residual three
patients, two patients had a scheduled mastectomy due to
the extensive extent of an index cancer and one had breast
conserving surgery because of the lesion localized 1 cm
just inferior to the index cancer within the same quadrant. 
In the 10 patients without a US correlate, the lesions in
six patients could not be localized. Of the four that
underwent a US-guided localization, US-guided needle
localization was used in one and carbon marking in three.
Although lesions are not defined on US with certainty,
localizations were performed in five lesions of four patients
for subtle sonographic lesions likely consistent with the
additional suspicious MR lesions. As the lesions without a
US correlate could not be localized, careful histological
examinations were requested at the area of any additional
MR lesions.
RESULTS
Patients and Lesions
Of the 149 total patients for whom MRI was used for
preoperative evaluation of breast cancer, 69 additional
suspicious breast lesions were detected by MRI in 62
patients (42%). Of those 69 lesions, 26 (38%) were
confirmed as cancers by histology. By MRI, 48 of 69
lesions (70%) revealed a mass, and 21 (30%)
demonstrated nonmass-like enhancements and the average
diameter of the 69 additional enhancing lesions in these 62
patients was 1.1 cm (range, 0.4 5.0 cm).
In addition, of these 62 patients with 69 lesions, 57
(92%) had a single additional lesion, four (6%) had two
lesions, and one (2%) had four lesions. Among 69 lesions,
additional cancers were diagnosed in 26 (38%) in 23
patients. Contralateral enhancing lesions were detected in
ten patients (16%), of which confirmed cancers in three
patients (5%). 
Pathological Outcomes of Additional Lesions
Evaluated with Targeted US
Of the 62 patients with additional lesions, 31 patients
with 38 lesions underwent targeted US. Histological
findings of these 38 lesions in 31 patients performed with
targeted US revealed cancers in 18 (47%) lesions, high-risk
lesions in two (5%), benign lesions in 15 (39%), and
unidentified lesions in three (8%) (Table 1). The latter
three lesions that were not confirmed by histological
examination were removed by a mastectomy in one
patient and breast conservative surgery with a wide extent
in two patients. 
Of the 38 lesions examined with targeted US, 27 (71%)
had a US correlate, which included 15 (56%, 15/27)
cancers (Fig. 1), two (7%, 2/27) high-risk lesions (lobular
carcinoma in situ and atypical ductal hyperplasia in each
one) and ten (37%, 10/27) benign lesions (Fig. 2). Of the
11 lesions without a US correlate, three (27%, 3/11)
proved to be cancerous (Fig. 3) and five (45%, 5/11) were
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Table 1. Pathologic Outcomes of Additional Suspicious
Lesions (n = 38) with the Performance of Targeted
US in 31 Patients with Breast Cancer
Pathology No. of Lesions (%)
Malignant 18  (47.4)
High risk  2 (5.2)
Benign 15  (39.5)
Unidentified histologically 3 (7.9)
Total 38  (100).benign as determined by mastectomy or breast conserving
surgery with additional excision (Fig. 4), however, three
(27%, 3/11) were not confirmed by histology. The cancer
rate was statistically higher in lesions with a US correlate
than in ones without a US correlate (p = 0.028) (Table 2).
Of 15 cancers with a US correlate US, ten (67%) were
confirmed as invasive ductal carcinoma, and five (33%) as
ductal carcinoma in situ. Of the three cancers without a US
correlate, two (67%) were ductal carcinoma in situ, and
one (33%) as an invasive ductal carcinoma. The difference
between invasive and in situ carcinoma was not statisti-
cally significant (p = 0.528). Of US correlate lesions identi-
fied by histology, the high-risk lesions included lobular
carcinoma in situ and atypical ductal hyperplasia for each
one. The benign lesions were diagnosed as papilloma in
three, fibroadenoma, stromal fibrosis, fibrocystic disease in
two each, and columnar cell change in one. Imaging
findings and pathological results of US correlate lesions are
summarized in Table 3.
Shin et al.
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ABC
Fig. 1. A 34-year-old woman with a 3-cm-sized palpable cancer of
the right breast.
A, B. A dynamic enhanced and subtracted T1-weighted sagittal
MR image shows a 3 cm, irregular-shaped, enhancing malignant
mass (arrow) (A). A small subareolar enhancing nodule
(arrowhead) is additionally noted in the subareolar region in a
different plane (B). 
C. A high signal intensity subareolar nodule (arrowhead) is noted
on the reverse subtracted image. 
D. Targeted US depicts a 0.7 cm sized hypoechoic nodule
(arrowhead) between the nipple and a palpable malignant mass
(arrow). A US-guided biopsy of an additional lesion revealed an
infiltrating ductal carcinoma. The surgical plan was changed from
conservative breast surgery to a modified radical mastectomy with
the consent of the patient.
DChanges in Surgical Management as a Result of
Targeted US
Of 31 patients who underwent targeted US, the surgical
plan was altered in 27 patients (87%) and not in four
patients. Targeted US justified a change in treatment for 22
patients (81%) and misled five patients (19%) into an
unnecessary surgical excision. 
Of 21 patients with US correlates, the surgical treatment
plan for 19 patients was altered preoperatively with the
consent of the patient. These 19 patients included 14 with
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Fig. 2. A 56-year-old woman with a nonpalpable US-detected cancer. 
A. A dynamic enhanced and subtracted T1-weighted sagittal MR image shows a spiculated malignant mass (arrow) in the upper outer
portion of the right breast. 
B, C. Multiple aggregated enhancing nodules (arrowhead) (B) are additionally noted in the lower outer portion of the right breast. These
nodules (arrowhead) show a high signal intensity on the reverse subtracted image (C).
D. An initial US shows an irregular hypoechoic mass (arrow) in the upper outer portion of the right breast. 
E. On targeted US, a hypoechoic nodule (arrowhead) that was not detected at an initial US is noted at the 9 o’clock position of the right
breast. The surgical biopsy after US-guided localization revealed an intraductal papilloma. 
DEadditional cancers, two with high-risk lesions and three
with benign lesions (one fibroadenoma and two intraductal
papillomas). Two patients with high-risk lesions underwent
conserving surgery and a wider excision. Even though the
US-guided core biopsy for three patients confirmed benign
lesions, these patients underwent conserving surgery and a
Shin et al.
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Fig. 3. A 40-year-old woman with a 1 cm palpable cancer of the left breast. 
A, B. Dynamic enhanced and subtracted T1-weighted sagittal MR images show a 1 cm intensely enhancing main mass (arrow) (A) in
addition to a 5 cm clumped segmental enhancement with washout (arrowheads) (B) in a different plane.
C. A high signal intensity (arrowheads) of a 5 cm clumped segmental enhancement is noted on the reverse subtracted image.
D. Initial US shows only a 1 cm hypoechoic mass (arrow) at a palpable site. 
E. Targeted US shows a normal-looking, but slightly heterogeneous parenchyma. We interpreted that the additional enhancing lesion on
MR had no US correlate. On a frozen section examination during the surgical operation, the additional enhancing lesion at the surround-
ing parenchyma revealed a malignancy, which was confirmed as an extensive intraductal carcinoma with an invasive ductal carcinoma
following mastectomy. The surgical plan was changed from conservative breast surgery to mastectomy without the consent of the
patient. 
DEwider excision, because the surgeon did not want to defer
the operation because of a personal concern of the patient
or delayed pathological results with the consensus of the
patient. Of the ten patients without US correlates, surgical
treatment was changed in eight patients. However, three
patients for whom cancers were confirmed subsequently
underwent mastectomy at the discretion of surgeon (two),
and conservative surgery with a wide excision during the
operation (one). Five patients underwent unnecessary wide
excision due to the difficulty in localizing the additional
lesions.
In 13 (76%) of 17 patients (14 with US correlates and 3
without US correlates) in whom MRI detected additional
cancers, the surgery was converted to mastectomy in ten
or additional contralateral conserving surgery in three. 
DISCUSSION
Breast MRI is generally accepted as the preferred
diagnostic method for patients with breast cancer because
of its high sensitivity (10 12). In contrast, the specificity of
breast MR images remains highly variable (37 100%) (10,
11). In situations where there is a high probability of
cancer such as preoperative staging, use of MRI can be
very helpful. In the current study, the detection of
additional lesions by MRI in breast cancer patients was
frequent (42%). Among the 69 additional lesions detected
by MRI, 26 (38%) were shown to be cancers following a
histological examination. 
Because of the need to biopsy and localize these lesions
Usefulness of Targeted Ultrasound for MR-Detected Lesions in Breast Cancer
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Fig. 4. A 43-year-old woman with a 1.5 cm palpable breast cancer. 
A. A dynamic enhanced and subtracted T1-weighted sagittal MR image shows a 1.8 cm, irregular-shaped, enhancing mass (arrow) at
the upper outer portion of the left breast. 
B. Two additional suspicious enhancing lesions with washout (arrowheads) were noted at a different quadrant. Targeted US could not
find a correlated lesion. Additional tissue excision and conserving surgery were performed due to this false positive finding of no US
correlate. The final pathological diagnosis was fibrocystic change.
C. High signal intensities of two additional lesions (arrowheads) are noted on the reverse subtracted image.
Table 2. The Presence of US Correlated Lesions and
Pathologic Outcomes of Additional Suspicious
Lesions on MR (n = 38) Evaluated with Targeted US
US Correlated Lesions
Pathology No. of Lesions (%) p value*
Presence Absence
Total 27/38 (71.1) 11/38 (28.9) 0.028
Malignant 15/27 (55.6) 03/11 (27.3)
High risk 2/27 (7.4) 0/11 (0)0.
Benign 10/27 (37.0) 05/11 (45.4)
Unidentified histologically 0 03/11 (27.3)
Note. * p value was calculated by Fisher’s exact test.initially seen only on MRI, and until recently, the lack of
biopsy systems that were MR compatible and commer-
cially available, we designed an alternative method. If a
lesion that is detected only on MRI can be found on US
through careful re-examination, the visualization of the
lesion on US will enable a US-guided intervention by a
skilled radiologist and allow the patients to possibly avoid
a multi-step surgery. Some investigators have previously
reported on the reliability of targeted ultrasound for
suspicious MRI-detected lesions (13 15). Because targeted
US might be complementary to a subjective US by
referencing MR imaging, this technical procedure is more
helpful in reducing the number of missed cancers than
using US alone or using US before MRI. In our study,
targeted US found 71% of the additional lesions seen only
on MR in breast cancer patients. In comparison to a
previous report where 23% of the cases were detected, we
suggest the basis for these differing results include the
selection of patients that had a high probability of cancer,
the more frequent use of bilateral whole breast ultrasound
due to unfamiliarity with a skillful MR-guided biopsy
technique, and an advantage in lesion detection due to the
relatively smaller-sized breasts of Asian women included
in the study that allowed routine use of a smaller film size
(eg. 18 24 cm) introduced for mammograms (3). Biopsy
or localization was successfully completed in all patients
with a US correlate, and 15 (71%) of these patients had
additional sites of cancer subsequently identified by MRI. 
Of these 31 patients who underwent targeted US,
carcinoma was found in 56% of patients that had a US
correlate; in comparison, cancer was identified in 27% of
patients lacking a US correlate. This difference was statisti-
cally significant (p = 0.028). Similar to a previous study, a
US correlate was more often observed for cancers in the
present study (3). Twenty lesions (74%) out of 27 with a
US correlate were detected as a mass (or small nodule) on
MRI and were observed more often for invasive forms
(67%) than for in situ forms (33%) (p = 0.528). 
Additional lesions that are verified by MRI may lead to
either a justified surgical excision or over-treatment. In a
previous study on preoperative MRI, planned surgical
management was altered in 26% of the cases (16). In our
study, we demonstrated that the targeted US results
altered subsequent surgical management from what had
been planned initially for 27 (87%) of all 31 patients who
underwent targeted US. Targeted US in addition to MRI
seems to contribute to an alteration in the surgical plan.
Targeted US justified the change in treatment for 22
patients (81%) and misled five patients (19%) to unneces-
sary surgical excision. The five over-treated patients who
underwent additional treatment had lesions without a US
correlate.
A retrospective study such as this has deficiencies. First,
histological confirmation was absent or unavailable in
some instances, because of the inability to conduct MRI-
guided percutaneous biopsy. Thus, excision of lesions
Shin et al.
482 Korean J Radiol 8(6), December 2007
Table 3. Imaging Findings and Pathologic Results of US Correlated Lesions (n = 27) with the Performance of Targeted US in 15
Patients with Breast Cancer
Pathology (n = 27) MR Findings US Findings 
Malignant
Invasive ductal carcinoma (10) Mass (7) Hypoechoic nodule
Segmental enhancement (2) Hypoechoic nodule
Ductal enhancement (1)  Hypoechoic nodule
Ductal carcinoma in situ  (5) Mass (4) Hypoechoic nodule
Linear enhancement (1)  Subtle heterogeneous area
High-risk
Lobular carcinoma in situ (1)  Mass (1) Small cystic nodules
Atypical ductal hyperplasia (1) Regional enhancement (1) Heterogeneous cystic nodule
Benign 
Papilloma (3)         Mass (1) Hypoechoic nodule
Segmental enhancement (1) Hypoechoic nodule
Focal area (1) Hypoechoic nodule
Fibrocystic change (2)     Mass (2) Hypoechoic nodule
Fibroadenoma (2) Mass (2) Hypoechoic nodule
Stromal fibrosis (2) Mass (2) Hypoechoic nodule
Heterogeneous hypoechoic area
Columnar cell change (1)    Mass (1) Hypoechoic noduleUsefulness of Targeted Ultrasound for MR-Detected Lesions in Breast Cancer
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without a US correlate sometimes resulted in sacrificing
large amounts of normal tissue to examine an MR-
suspicious area. This is a serious drawback for targeted US.
Therefore, we speculate that an MR-guided biopsy
provides the unique ability to identify these lesions that are
not visualized by US (17, 18). Second, although US in this
study was performed by four skilled breast imaging radiol-
ogists and carefully correlated with additional imaging
studies, US interpretation is highly dependent upon both
the operator and the equipment. As for the US findings in
our study, radiologists tend to search for a sonographic
hypoechoic lesion in order for it to be considered as
suspicious. There may be a chance of missing the
additional lesion that would be seen as a hyperechoic or
isoechoic lesion by targeted US.
It has been our experience that if a suspicious lesion in
patients with breast cancer is additionally depicted only on
MRI, re-examination with another modality, specifically
ultrasound, can improve the accuracy of identification and
characterization of the lesion, thereby increasing
confidence in the application of an intervention. However,
our results also highlighted the need of MR-guided biopsies
in some cases. 
In conclusion, targeted US can play a useful role in the
evaluation of additional suspicious MR lesions in breast
cancer patients, but is limited in lesions without a US
correlate.
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